Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Pediatric Refractory Solid Tumors
NCT02164838Phase 1Completed
- Sponsor
- Children's Oncology Group
- Start
- Sep 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of axitinib in solid tumor and renal cell carcinoma (RCC), sponsored by Children's Oncology Group. Primary endpoints: Adverse events as assessed by CTCAE version 4.0 at 28 days, Maximum Tolerated Dose of axitinib at 28 days and 1 more. Started Sep 2014; status: completed.
02
Drugs
axitinib
03
Conditions
solid tumorrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02164838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164838.